Protein Expression Platform Research Articles

The proteome of Nicotiana benthamiana is shaped by extensive protein processing.

Processing by proteases irreversibly regulates the fate of plant proteins and hampers the production of recombinant proteins in plants, yet only few processing events have been described in agroinfiltrated Nicotiana benthamiana, which has emerged as the main transient protein expression platform in plant science and molecular pharming. Here, we used in-gel digests and mass spectrometry to monitor the migration and topography of 5040 plant proteins within a protein gel. By plotting the peptides over the gel slices, we generated peptographs that reveal where which part of each protein was detected within the protein gel. These data uncovered that 60% of the detected proteins have proteoforms that migrate at lower than predicted molecular weights, implicating extensive proteolytic processing. This analysis confirms the proteolytic removal and degradation of autoinhibitory prodomains of most but not all proteases, and revealed differential processing within pectinemethylesterase and lipase families. This analysis also uncovered intricate processing of glycosidases and uncovered that ectodomain shedding might be common for a diverse range of receptor-like kinases. Transient expression of double-tagged candidate proteins confirmed processing events in vivo. This large proteomic dataset implicates an elaborate proteolytic machinery shaping the proteome of N. benthamiana.

Improving transient protein expression in agroinfiltrated Nicotiana benthamiana.

Agroinfiltration of Nicotiana benthamiana is routinely used in plant science and molecular pharming to transiently express proteins of interest. Here, we discuss four phenomena that should be avoided to improve transient expression. Immune responses can be avoided by depleting immune receptors and employing pathogen-derived effectors; transcript degradation by using silencing inhibitors or RNA interference machinery mutants; endoplasmic reticulum stress by co-expressing chaperones; and protein degradation can be avoided with subcellular targeting, protease mutants and co-expressing protease inhibitors. We summarise the reported increased yields for various recombinant proteins achieved with these approaches and highlight remaining challenges to further improve the efficiency of this versatile protein expression platform.

Seed plastids: A novel platform for recombinant protein expression.

Seed plastids: A novel platform for recombinant protein expression.

Construction of a stable expression HEK293T engineered cell line adapted to high-density suspension culture

The HEK293 cell line has received FDA approval and is increasingly used to produce therapeutic glycoproteins. However, the cell line faces the challenge of long-term expression instability. This problem could be solved by specifically integrating exogenous genes into stable sites and developing a HEK293 cell platform to efficiently and stably express recombinant proteins with large-scale suspension culture. The study uses CRISPR/Cas9 and recombinase-mediated cassette exchange (RMCE) technologies to integrate a variety of exogenous genes into specific chromosomal sites, such as the hROSA26 site, AAVS1 site, and CCR5 site. We evaluated the stability and expression intensity of exogenous proteins at different insertion sites under suspension culture conditions. A monoclonal cell line expressing enhanced green fluorescent protein (EGFP) is obtained using CRISPR/Cas9-mediated specific integration. The positive monoclonal cell lines express EGFP after 60 consecutive passages, and no significant differences in protein expression titer are observed. These results show that, under suspension culture conditions, the hROSA26 locus could stably express exogenous proteins after 60 generations. HEK293 cell lines integrating HSA (68 kDa) and IFNβ-HSA (89 kDa) genes at the above three sites were obtained respectively using Bxb1-mediated RMCE technology, and batch experiments demonstrated their expression capacity. In summary, a stable and efficient protein expression platform of HEK293 cells is successfully constructed and could be adapted to serum-free suspension culture.

Construction and testing of Yarrowia lipolytica recombinant protein expression chassis cells based on the high-throughput screening and secretome

BackgroundIn the recombinant protein market with broad economic value, the rapid development of synthetic biology has made it necessary to construct an efficient exocrine expression system for the different heterologous proteins. Yarrowia lipolytica possesses unique advantages in nascent protein transport and glycosylation modification, so it can serve as a potential protein expression platform. Although the Po1 series derived from W29 is often used for the expression of the various heterologous proteins, the ability of W29 to secrete proteins has not been verified and the Po1 series has been found to be not convenient for further gene editing.ResultsA total of 246 Y. lipolytica strains were evaluated for their secretory capacity through performing high-throughput screening in 48-well plate. Thereafter, following two rounds of shake flask re-screening, a high-secreting protein starting strain DBVPG 5851 was obtained. Subsequently, combined with the extracellular protein types and relative abundance information provided by the secretome of the starting strain, available chassis cell for heterologous protein expression were preliminarily constructed, and it was observed that the most potential signal peptide was derived from YALI0D20680g.ConclusionsThis study offers a novel perspective on the diversification of Y. lipolytica host cells for the heterologous protein expression and provides significant basis for expanding the selection space of signal peptide tools in the future research.

Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies

The consecutive launch of mRNA vaccines like mRNA-1273, BNT 162b2, and GEMCOVAC®-19 against COVID-19 has triggered the debate of long-term expression, safety, and genomic integration of the mRNA vaccine platforms. In the present study, we examined the longevity of antigenic protein expression of mRNA-614 and mRNA-S1LC based on self-amplifying mRNA (SAM) in Expi-293F™, HEK-293 T, and ARPE-19 cells. The protein expression was checked by sandwich-ELISA, FACS, luciferase activity assay, and Western blot. The transcribed antigenic mRNA was sequenced and found to be un-mutated. Additionally, no genomic integration of the reverse transcribed mRNA was observed even up to 7 days post-transfection as verified by PCR. Furthermore, we have generated high-quality 3D structures of non-structural proteins (nsPs) in silico and the genes encoding for the nsPs were cloned and expressed using the T7 system. Findings from the current study have strengthened the fact that the alphavirus-based SAM platform has the potential to become a modality in the upcoming years.

End-to-End Semi-automated Mid-scale Protein Screening Platform for Drug Discovery Research.

The drug discovery landscape is ever-evolving and constantly demands revolutionary technology advancements in protein expression and production laboratories. We have built a higher-throughput mid-scale semi-automated protein expression and screening platform to accelerate drug discovery research. The workflow described here enables comprehensive expression and purification screening assessment of challenging or difficult-to-express recombinant proteins in a fast and efficient manner by delivering small but sufficient amounts of high-quality proteins. The platform has been implemented for a wide range of applications that include identification of optimal constructs and chaperones for poorly expressing proteins, assessment of co-expression partners for expressing stable multiprotein complexes, and suitable buffer/additive screening for insoluble or aggregation-prone proteins. The approach allows parallel expression, purification, and characterization of 24 different samples using co-infection or a polycistronic approach in insect cells and enables parallel testing of multiple parameters to improve protein yields. The strategy has been successfully adopted for screening intracellular and secreted proteins in Escherichia coli, mammalian transient expression, and baculovirus expression vector systems. Proteins purified from this platform are used for several structural and functional screens, such as negative staining, biochemical activity assays, mass spectrometry, surface plasmon resonance, and DNA-encoded chemical library screens. In this article, for simplicity, we have focused on detailed expression and purification screening of intracellular protein complexes from insect cells. © 2023 Wiley Periodicals LLC. Basic Protocol 1: Baculovirus generation via homologous recombination Support Protocol 1: Anti-glycoprotein 64 antibody assay Basic Protocol 2: Generation of insect cell biomass expressing target protein(s) Basic Protocol 3: Mid-scale affinity purification Support Protocol 2: Automated method for affinity purification on Hamilton STAR Basic Protocol 4: Size exclusion chromatography Support Protocol 3: Chromeleon 7 operation on Vanquish Duo.

The Role of the PAA1 Gene on Melatonin Biosynthesis in Saccharomyces cerevisiae: A Search of New Arylalkylamine N-Acetyltransferases

Recently, the presence of melatonin in fermented beverages has been correlated with yeast metabolism during alcoholic fermentation. Melatonin, originally considered a unique product of the pineal gland of vertebrates, has been also identified in a wide range of invertebrates, plants, bacteria, and fungi in the last two decades. These findings bring the challenge of studying the function of melatonin in yeasts and the mechanisms underlying its synthesis. However, the necessary information to improve the selection and production of this interesting molecule in fermented beverages is to disclose the genes involved in the metabolic pathway. So far, only one gene has been proposed as involved in melatonin production in Saccharomyces cerevisiae, PAA1, a polyamine acetyltransferase, a homolog of the vertebrate’s aralkylamine N-acetyltransferase (AANAT). In this study, we assessed the in vivo function of PAA1 by evaluating the bioconversion of the different possible substrates, such as 5-methoxytryptamine, tryptamine, and serotonin, using different protein expression platforms. Moreover, we expanded the search for new N-acetyltransferase candidates by combining a global transcriptome analysis and the use of powerful bioinformatic tools to predict similar domains to AANAT in S. cerevisiae. The AANAT activity of the candidate genes was validated by their overexpression in E. coli because, curiously, this system evidenced higher differences than the overexpression in their own host S. cerevisiae. Our results confirm that PAA1 possesses the ability to acetylate different aralkylamines, but AANAT activity does not seem to be the main acetylation activity. Moreover, we also prove that Paa1p is not the only enzyme with this AANAT activity. Our search of new genes detected HPA2 as a new arylalkylamine N-acetyltransferase in S. cerevisiae. This is the first report that clearly proves the involvement of this enzyme in AANAT activity.

Abstract 5323: Accelerating the drug discovery process with an automated high-throughput protein production and characterization platform for AI-driven antibody development of immunotherapy

Abstract The demonstrated effectiveness and vast potential of large molecule therapeutics have driven biopharmaceutical companies to change the ways by which they discover and develop novel biologic therapies. While the conventional antibody discovery process via animal immunization and in vivo hypermutation can generate sufficient hits for functional screening, this approach can only cover a limited subset of sequence diversity. In silico, artificial intelligence (AI) driven methods, by contrast, have the potential to cover 2-3 orders of magnitude more sequence diversity compared to conventional methods and more rapidly produce a drug candidate with a superior safety and efficacy profile. However, this approach requires wet lab validation of predicted sequences as well as targeted data generation to improve AI-predicted rankings. Traditional wet lab methods for protein generation and characterization are expensive, time consuming, and prone to human error. These limitations restrict the overall potential benefit of the AI-driven antibody discovery process. To accelerate this process, which consists of a complex series of cycles spanning different functional teams, a substantial increase in the throughput of the end-to-end production and characterization workflow is established in-house such that 104 antibodies with property data can be generated and analyzed within a short period of time. BioMap has implemented a highly integrated and automated protein expression, purification, and characterization platform linked with a unified informatics system to eliminate as much manual operation as possible. This high-throughput robotic platform interweaves multiple procedures including plasmid preparation, cell dispensing, mammalian transfection, protein purification, and characterization, and it is coupled to our in-house informatics system and database. Empowered by state-of-the-art liquid handling system and well-established experimental protocols, the integrated facility is capable of the delivery of 103 protein samples from plasmids in ten days within a single batch. Benefiting from our robust transient expression platform, the production scale ranges from 0.5 to 30 mL with an average antibody yield of 300 mg/L. The high-throughput workflow brings a challenge to track the provenance of each protein and manage data flow across different stations. To address this bottleneck, a well-defined informatics platform and database have been developed to provide sample registration, interface with lab instruments, experimental process tracking, and automated data recording and analysis. The implementation of this system provides a massive amount of high-quality data available for AI training and validation with a very short turnover time and enables AI-driven development of next-generation biologics. Citation Format: Zhehao Xiong, Wei Jiang, Lijun Xia, Jianhua Huang, Cheng-chi Chao. Accelerating the drug discovery process with an automated high-throughput protein production and characterization platform for AI-driven antibody development of immunotherapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5323.

Strategic optimization of conditions for the solubilization of GST-tagged amphipathic helix-containing ciliary proteins overexpressed as inclusion bodies in E. coli

Expression of affinity-tagged recombinant proteins for crystallography, protein–protein interaction, antibody generation, therapeutic applications, etc. mandates the generation of high-yield soluble proteins. Although recent developments suggest the use of yeast, insect, and mammalian cell lines as protein expression platforms, Escherichia coli is still the most popular, due mainly to its ease of growth, feasibility in genetic manipulation and economy. However, some proteins have a spontaneous tendency to form inclusion bodies (IBs) when over-expressed in bacterial expression systems such as E. coli, thus posing a challenge in purification and yield. At times, small peptides undergo degradation during protein production and hence using suitable tags could circumvent the problem. Although several independent techniques have been used to solubilize IBs, these cannot always be applied in a generic sense. Although tagging a GST moiety is known to enhance the solubility of fusion proteins in E. coli, resulting in yields of 10–50 mg/L of the culture, the inherent nature of the protein sequence at times could lead to the formation of IBs. We have been working on a Myc Binding Protein-1 orthologue, viz. Flagellar Associated Protein 174 (FAP174) from the axoneme of Chlamydomonas reinhardtii that binds to an A-Kinase Anchoring Protein 240 (AKAP240) which has been annotated as Flagellar Associated Protein 65 (FAP65). Using an in-silico approach, we have identified two amphipathic helices on FAP65 (CrFAP65AH1 and CrFAP65AH2) that are predicted to bind to FAP174. To test this prediction, we have cloned the GST-tagged peptides, and overexpressed them in E. coli that have resulted in insoluble IBs. The yields of these over-expressed recombinant proteins dropped considerably due to IB formation, indicating aggregation. An integrated approach has been used to solubilize four highly hydrophobic polypeptides, viz. two amphipathic helices and the respective proline variants of FAP65. For solubilizing these polypeptides, variables such as non-denaturing detergents (IGEPAL CA-630), changing the ionic strength of the cell lysis and solubilization buffer, addition of BugBuster®, diluting the cell lysate and sonication were introduced. Our statistically viable results yielded highly soluble and functional polypeptides, indiscreet secondary structures, and a yield of ~ 20 mg/L of the E. coli culture. Our combinatorial strategy using chemical and physical methods to solubilize IBs could prove useful for hydrophobic peptides and proteins with amphipathic helices.

Needle in a Haystack: A Pilot Study Combining Single-Cell Multiomics with Clinical NGS-MRD Sequencing to Search for Circulating Clonotypic Dedifferentiated Myeloma Cells

Multiple myeloma (MM) is a heterogenous disease in which clonal evolution or preexisting reservoirs of phenotypically divergent cells may be harbingers of therapeutic resistance. Prior research has suggested the presence of myeloma cells with immunophenotypic and expression profiles dedifferentiated from that of terminally differentiated plasma cells that may be found in circulation, marrow, or potentially other lymphoid compartments; however, this has not been conclusively demonstrated in patients. The identification of such clonotypic myeloma cells could lead to a better understanding of myeloma biology and resistance, and inform therapies targeted at these populations, and single-cell technologies provide the granularity to characterize them. Next-generation sequencing (NGS)-based measurable residual disease (MRD) clinical-grade assays (eg. clonoSEQ®, Adaptive Biosciences) identify individuals’ unique heavy and light chain sequences. Theoretically this sequencing data could be overlaid with research-grade single-cell multiomics to identify clusters of clonotypic cells with variable differentiation. In this pilot study using the Enhanced Single Cell Analysis with Protein Expression (ESCAPE) platform (Singleron Biotechnologies) we aimed to identify peripherally circulating clonotypic MM cells by their NGS-MRD sequence and simultaneously determine whether their multiomic profile reflected possible dedifferentiated clusters found in paired marrow. Using scRNA-Seq (10x Genomics) data previously generated at our site from bone marrow mononuclear cells we identified MM cell clusters enriched for differentially expressed genes known to be expressed in B-cells and plasmablasts. These genes included CD19, PAX5, BCL6, EZH2, STMN1, HMGB2, MKI67 and CD27. We next sought to assay the peripheral blood mononuclear cells (PBMC) of patients (n=2) with an overrepresentation of cells in these clusters. To evaluate both the transcriptomic and immunophenotypic profiles of the PBMCs at single-cell resolution we utilized Singleron's Immune Profiling panel on the ESCAPE platform. Using Singleron's MapSuite™ analysis pipeline, we annotated cell-type classifications, and highlighted cells within the mature B-cell/plasma cell differentiation spectrum (Figure A). Within this subset, we attempted to identify gene expression reflective of the previously identified "dedifferentiated” marrow clusters with specific genes of interest, but found that there was not significant overlap. Heatmaps comparing the 5 peripheral subclusters with marrow plasma cells demonstrate some concordance with the marrow subclusters, with examination of these overlaps ongoing, but these were not the "dedifferentiated” marrow clusters. The included patients also had clonoSEQ® identification sequences of heavy chain and/or light chain available. By cross-referencing the NGS-MRD sequence data (clonoSEQ®, Adaptive Biosciences), we were able to use ESCAPE-Seq to identify definitive clonotypic circulating MM cells within the PBMC samples at single cell granularity. Among PBMCs from sample 2 we were able to identify circulating clonotypic myeloma cells with 100% match to the IgH and IgK MRD sequences, which also represented the dominant V(D)J clonotype in peripheral circulating. Concomitant single-cell surface protein analysis of this clonotypic cell population demonstrated significant expression of CD38, without significant differential expression of CD138 nor surface markers of B-cells (Figure B). While these data are preliminary and studies are ongoing, we successfully leveraged clinical-level MRD sequencing data to inform single-cell multiomics, a potentially powerful translational research pathway for any hematologic malignancy in which NGS-MRD is clinically available. We definitively identified a small subset of circulating MM cells and used the ESCAPE platform to efficiently generate a multiomics profile. This profile suggested elevated CD38 expression without elevated CD138 expression, which previously has been associated with dedifferentiated plasma cells and plasmablasts, although further analyses are ongoing. In future studies, we will enrich for B-lymphoid spectrum cells prior to single-cell analytics. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Genetic engineering of baculovirus-insect cell system to improve protein production.

The Baculovirus Expression Vector System (BEVS), a mature foreign protein expression platform, has been available for decades, and has been effectively used in vaccine production, gene therapy, and a host of other applications. To date, eleven BEVS-derived products have been approved for use, including four human vaccines [Cervarix against cervical cancer caused by human papillomavirus (HPV), Flublok and Flublok Quadrivalent against seasonal influenza, Nuvaxovid/Covovax against COVID-19], two human therapeutics [Provenge against prostate cancer and Glybera against hereditary lipoprotein lipase deficiency (LPLD)] and five veterinary vaccines (Porcilis Pesti, BAYOVAC CSF E2, Circumvent PCV, Ingelvac CircoFLEX and Porcilis PCV). The BEVS has many advantages, including high safety, ease of operation and adaptable for serum-free culture. It also produces properly folded proteins with correct post-translational modifications, and can accommodate multi-gene– or large gene insertions. However, there remain some challenges with this system, including unstable expression and reduced levels of protein glycosylation. As the demand for biotechnology increases, there has been a concomitant effort into optimizing yield, stability and protein glycosylation through genetic engineering and the manipulation of baculovirus vector and host cells. In this review, we summarize the strategies and technological advances of BEVS in recent years and explore how this will be used to inform the further development and application of this system.

The Role of Tryptophan in π Interactions in Proteins: An Experimental Approach.

In proteins, the amino acids Phe, Tyr, and especially Trp are frequently involved in π interactions such as π–π, cation−π, and CH−π bonds. These interactions are often crucial for protein structure and protein–ligand binding. A powerful means to study these interactions is progressive fluorination of these aromatic residues to modulate the electrostatic component of the interaction. However, to date no protein expression platform is available to produce milligram amounts of proteins labeled with such fluorinated amino acids. Here, we present a Lactococcus lactis Trp auxotroph-based expression system for efficient incorporation (≥95%) of mono-, di-, tri-, and tetrafluorinated, as well as a methylated Trp analog. As a model protein we have chosen LmrR, a dimeric multidrug transcriptional repressor protein from L. lactis. LmrR binds aromatic drugs, like daunomycin and riboflavin, between Trp96 and Trp96′ in the dimer interface. Progressive fluorination of Trp96 decreased the affinity for the drugs 6- to 70-fold, clearly establishing the importance of electrostatic π–π interactions for drug binding. Presteady state kinetic data of the LmrR–drug interaction support the enthalpic nature of the interaction, while high resolution crystal structures of the labeled protein–drug complexes provide for the first time a structural view of the progressive fluorination approach. The L. lactis expression system was also used to study the role of Trp68 in the binding of riboflavin by the membrane-bound riboflavin transport protein RibU from L. lactis. Progressive fluorination of Trp68 revealed a strong electrostatic component that contributed 15–20% to the total riboflavin-RibU binding energy.

Evaluation of Methylotrophic Yeast Ogataea thermomethanolica TBRC 656 as a Heterologous Host for Production of an Animal Vaccine Candidate.

Multiple yeast strains have been developed into versatile heterologous protein expression platforms. Earlier works showed that Ogataea thermomethanolica TBRC 656 (OT), a thermotolerant methylotrophic yeast, can efficiently produce several industrial enzymes. In this work, we demonstrated the potential of this platform for biopharmaceutical manufacturing. Using a swine vaccine candidate as a model, we showed that OT can be optimized to express and secrete the antigen based on porcine circovirus type 2d capsid protein at a respectable yield. Crucial steps for yield improvement include codon optimization and reduction of OT protease activities. The antigen produced in this system could be purified efficiently and induce robust antibody response in test animals. Improvements in this platform, especially more efficient secretion and reduced extracellular proteases, would extend its potential as a competitive platform for biopharmaceutical industries.

Overexpressing CrePAPS Polyadenylate Activity Enhances Protein Translation and Accumulation in Chlamydomonas reinhardtii.

The alga Chlamydomonas reinhardtii is a potential platform for recombinant protein expression in the future due to various advantages. Dozens of C. reinhardtii strains producing genetically engineered recombinant therapeutic protein have been reported. However, owing to extremely low protein expression efficiency, none have been applied for industrial purposes. Improving protein expression efficiency at the molecular level is, therefore, a priority. The 3′-end poly(A) tail of mRNAs is strongly correlated with mRNA transcription and protein translation efficiency. In this study, we identified a canonical C. reinhardtii poly(A) polymerase (CrePAPS), verified its polyadenylate activity, generated a series of overexpressing transformants, and performed proteomic analysis. Proteomic results demonstrated that overexpressing CrePAPS promoted ribosomal assembly and enhanced protein accumulation. The accelerated translation was further verified by increased crude and dissolved protein content detected by Kjeldahl and bicinchoninic acid (BCA) assay approaches. The findings provide a novel direction in which to exploit photosynthetic green algae as a recombinant protein expression platform.

Chemically Modified mocRNAs for Highly Efficient Protein Expression in Mammalian Cells.

mRNA has recently been established as a new class of therapeutics, due to its programmability and ability to produce proteins of interest rapidly in vivo. Despite its demonstrated utility, mRNA as a protein expression platform remains limited by its translational capacity and RNA stability. Here, we introduce messenger-oligonucleotide conjugated RNAs (mocRNAs) to enable site-specific, robust, and modularized encoding of chemical modifications for highly efficient and stable protein expression. In mocRNA constructs, chemically synthesized oligonucleotides are ligated to the 3' terminus of mRNA substrates to protect poly(A) tails from degradation, without compromising their potency in stimulating translation. As a proof-of-concept, mocRNAs modified by deadenylase-resistant oligonucleotides result in augmented protein production by factors of 2-4 in human HeLa cells and by 10-fold in primary rat cortical neuronal cultures. By directly linking enzymatic and organic synthesis of mRNA, we envision that the mocRNA design will open new avenues to expand the chemical space and translational capacity of RNA-based vectors in basic research and therapeutic applications.

Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies.

Rationale: Messenger RNA (mRNA) vaccine outperforms other kinds of cancer immunotherapy due to its high response rates, easy preparation, and wide applicability, which is considered as one of the most promising forms of next-generation cancer therapies. However, the inherent instability and insufficient protein expression duration of mRNA limit the efficacy and widespread application of the vaccine.Methods: Here, we first tested the possibility of a novel circular RNA (circRNA) platform for protein expression and compare its duration with linear RNA. Then, we developed a lipid nanoparticle (LNP) system for circRNA delivery in vitro and in vivo. Next, the innate and adaptive immune response of circRNA-LNP complex was evaluated in vivo. The anti-tumor efficacy of circRNA-LNP was further confirmed in three tumor models. Finally, the possibility of combination therapy with circRNA-LNP and adoptive cell transfer therapy was further investigated in a late-stage tumor model.Results: We successfully increased the stability of the RNA vaccine by circularizing the linear RNA molecules to form highly stable circRNA molecules which exhibited durable protein expression ability. By encapsulating the antigen-coding circRNA in LNP enabling in vivo expression, we established a novel circRNA vaccine platform, which was capable of triggering robust innate and adaptive immune activation and showed superior anti-tumor efficacy in multiple mouse tumor models.Conclusions: Overall, our circRNA vaccine platform provides a novel prospect for the development of cancer RNA vaccines in a wide range of hard-to-treat malignancies.

Building a Versatile Protein Production Platform Using Engineered Trichoderma reesei.

Trichoderma reesei has an extremely high capacity for synthesizing and secreting proteins, thus exhibiting promise as an expression platform for heterologous proteins. However, T. reesei secretes large amounts of native proteins, which hinders its widespread application for heterologous protein production. Here, we designed and built a series of T. reesei chassis using an iterative gene deletion approach based on an efficient genome editing system. Donor DNAs with specially designed construct facilitated screening of positive deletion strains without ectopic insertion. Finally, marker-free T. reesei chassis with lower rates of native protein secretion and low levels of extracellular protease activity were constructed after 11 consecutive rounds of gene deletion. Higher production levels of three heterologous proteins─a bacterial xylanase XYL7, a fungal immunomodulatory protein LZ8, and the human serum albumin HSA─were achieved with these chassis using the cbh1 promoter. It is possible that diverse high-value proteins might be produced at a high yield using this engineered platform.

Advances of Glycometabolism Engineering in Chinese Hamster Ovary Cells

As the most widely used mammalian cell line, Chinese hamster ovary (CHO) cells can express various recombinant proteins with a post translational modification pattern similar to that of the proteins from human cells. During industrial production, cells need large amounts of ATP to support growth and protein expression, and since glycometabolism is the main source of ATP for cells, protein production partly depends on the efficiency of glycometabolism. And efficient glycometabolism allows less glucose uptake by cells, reducing production costs, and providing a better mammalian production platform for recombinant protein expression. In the present study, a series of progresses on the comprehensive optimization in CHO cells by glycometabolism strategy were reviewed, including carbohydrate intake, pyruvate metabolism and mitochondrial metabolism. We analyzed the effects of gene regulation in the upstream and downstream of the glucose metabolism pathway on cell’s growth and protein expression. And we also pointed out the latest metabolic studies that are potentially applicable on CHO cells. In the end, we elaborated the application of metabolic models in the study of CHO cell metabolism.

Application of molecular farming based on barley plant (Hordeum vulgare L.) platform: A Review

Historically, humans have used plants as a source of medicine since ancient times. But the use of transgenic plants in molecular farming is a major source of molecular drugs. The use of molecular farming offers a promising prospect for producing of large-scale, low-cost pharmaceutical and industrial compounds. The results of this research include the production of plasma proteins, enzymes, growth factors, vaccines and antibodies. As plants can offer an inexpensive and convenient platform for the large-scale production of recombinant proteins with various functions, the driven force from the giant market for recombinant protein pharmaceuticals and industrial enzymes makes this subject grow and advance very quickly. With an increased demand for biopharmaceuticals, high costs, and inefficiency of current production systems, transgenic plants have received more attention as a new generation of bioreactors; but determining the best plant platform for the expression of recombinant proteins is one of the critical issues in molecular farming. So far, several expression platforms on this basis for the production of foreign proteins have been evaluated. Among these, the use of dry cereal seeds is one of the most efficient methods used to accumulate recombinant proteins. On the other hand, barley is a right candidate for recombinant protein expression platforms due to its easy cultivation management, high protein content, and low protein diversity, high adaptability to climatic conditions and low production costs. Besides, the highly self-pollinating nature of barley, along with its inability to produce fertile hybrids with related crops or wild species, creates a genetic mechanism, which practically prevents the unwanted dispersion of genetically modified germplasm under field conditions. Iran is also one of the centers of barley diversity in the Middle East, and the vast genetic variety, and nativeness of barley in this region is of particular importance to breeders.